<DOC>
	<DOCNO>NCT02611921</DOCNO>
	<brief_summary>The purpose study determine intranasal ketamine show initial evidence safety , tolerability efficacy treatment social impairment individual Autism Spectrum Disorder .</brief_summary>
	<brief_title>Study Intranasal Ketamine Social Impairment Autism Spectrum Disorder</brief_title>
	<detailed_description>To address significant need effective treatment core symptom Autism Spectrum Disorder ( ASD ) , trial design double-blind , placebo-controlled crossover pilot study intranasal ketamine 24 individual ASD age 12- 30 year use novel quantitative eye-tracking outcome measure assess impact drug social impairment . Additionally , develop ketamine-focused personalized medicine approach ASD , investigator include pharmacokinetic , molecular pharmacodynamic , electrophysiological assessment initial systematic study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Ages 12 30 year old . Weight equal great 50 kg . General good health determine physical exam , medical history , laboratory work , EKG . Diagnostic Statistical Manual Mental Disorders 5th Edition diagnosis autism spectrum disorder ( associate Fragile X Syndrome know genetic syndrome ) confirm Autism Diagnostic Observation Schedule screen previous ( within last 5 year ) available . Valid Intelligence Quotient ( IQ ) score great equal 50 confirm via testing ( Leiter3 ) screen previous ( within last 5 year , valid test acceptable ) . Clinical Global ImpressionsSeverity score 4 ( Moderately Ill ) . Score 10 Social Withdrawal subscale Aberrant Behavior Checklist . Stable dose concomitant psychotropic medication five halflives prior screen visit study . Presence parent/guardian significant caregiver willing serve informant behavioral outcome measure . Presence comorbid schizophrenia , schizoaffective disorder , bipolar disorder psychosis , bipolar disorder psychosis otherwise specify . Comorbid diagnose determined psychiatrist clinical interview use Diagnostic Statistical Manual Mental Disorders 5th Edition diagnostic criterion . History drug alcohol abuse . Presence cardiac disease include coronary artery disease , congestive heart failure , uncontrolled hypertension per medical history ( individual ≥ 2 blood pressure reading ≥140/90 screen/baseline exclude ) . Airway instability , tracheal surgery , tracheal stenosis per medical history . Central nervous system mass hydrocephalus per medical history . Porphyria , thyroid disorder , thyroid medication use per medical history . Glaucoma cause increase intraocular pressure per medical history . Allergy ketamine . Current use drug concomitant modification noncompetitive NmethylDaspartate glutamate activity ( acamprosate , amantadine , memantine , dcycloserine etc . ) For female subject child bear potential , positive pregnancy test . Any major chronic medical chronic respiratory illness consider uncontrolled Principal Investigator . Inability tolerate study procedure study drug per discretion Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>Social Impairment</keyword>
	<keyword>Autism</keyword>
	<keyword>Autistic Disorder</keyword>
</DOC>